Press releases
-
-
-
-
-
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
-
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
-
-
-
-
-
-
-
-
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
-
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
-
-
-
Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR to Present at Upcoming Scientific Conferences
-
Internal link ProQR to Present at Upcoming Investor Conferences
-
-
-
-